Chemomab Therapeutics (CMMB) Liabilities and Shareholders Equity (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $13.8 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 18.58% year-over-year to $13.8 million; the trailing twelve-month figure through Dec 2025 stood at $50.1 million (down 28.81% YoY), and the FY2025 full-year result was $13.8 million, down 18.58% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $13.8 million, up from $12.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $70.5 million in Q2 2021 and bottomed at $11.1 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $26.1 million (2023), against an average of $35.2 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity jumped 777.1%; it then sank 53.37% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $64.4 million in 2021, then slumped by 33.08% to $43.1 million in 2022, then sank by 48.56% to $22.2 million in 2023, then retreated by 23.42% to $17.0 million in 2024, then retreated by 18.58% to $13.8 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $13.8 million (Q4 2025), $12.4 million (Q3 2025), and $11.1 million (Q2 2025), per Business Quant data.

Peer Comparison